Fosamax and Osteonecrosis of the Jaw: Examining the Evidence for Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Pharmacovigilance

The legacy of general health and science information has long provided a foundation for understanding how environmental and pharmaceutical factors influence human physiology. Within this broad context, the dissemination of knowledge about medication side effects has evolved from basic safety warnings to more nuanced risk assessments. Historically, public health communications emphasized general wellness principles, but as scientific inquiry deepened, specific drug-related adverse events began to receive focused attention. This shift reflects a natural progression from population-level health guidance to individualized risk evaluation, particularly for medications with prolonged use profiles. The bisphosphonate class, including Fosamax, emerged as a subject of interest due to its widespread prescription for bone density management. Initial health information frameworks addressed general efficacy and common tolerability issues, yet subsequent observational data prompted a more targeted examination of rare but serious outcomes. This transition from broad health education to specialized pharmacovigilance sets the stage for considering occupational exposure scenarios. In mass production environments, where workers may handle pharmaceutical compounds or their precursors, the same risk assessment principles apply but with distinct exposure parameters. The pivot from patient-oriented health information to occupational health considerations requires acknowledging that manufacturing personnel face different exposure routes, durations, and intensities compared to therapeutic users. Thus, the general health context now serves as a baseline for exploring how occupational settings might modify risk profiles for conditions such as osteonecrosis of the jaw.

Understanding Fosamax and Its Mechanism of Action

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ involves bone exposure in the oral cavity, often accompanied by pain, swelling, and infection. Diagnosis is typically based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or radiation-induced osteonecrosis. The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but research suggests that bisphosphonates, including alendronate, suppress bone turnover by inhibiting osteoclast activity. This suppression can impair the jawbone's ability to remodel and repair, particularly in response to local trauma or infection. A multiscale characterization of jawbone tissue has provided comprehensive information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights that the jawbone may have unique structural and cellular properties that make it more susceptible to the effects of bisphosphonate therapy. Risk factors for developing ONJ while taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Timeline of Risk and Population-Level Evidence

The timeline between Fosamax exposure and documented harm varies. The time to onset of symptoms, which may include jaw pain or other oral issues, can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Population-level data from a cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink (CPRD Aurum) provides further insight into the risk timeline. The study found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This suggests a cumulative dose-response relationship, where longer exposure to Fosamax increases the likelihood of ONJ, though the overall risk remains small.

Causation Considerations and Adequacy of Warnings

Regarding causation considerations for affected patients, the evidence indicates that Fosamax can be a contributing factor to ONJ, particularly when combined with other risk factors such as dental procedures or comorbidities. The drug's labeling acknowledges that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that discontinuation may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, causation is not absolute, as ONJ can occur spontaneously without bisphosphonate use. The adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's prescribing information, which includes a specific section on osteonecrosis of the jaw under warnings and precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section outlines risk factors and management strategies, such as considering discontinuation before invasive dental procedures. In summary, studies show that Fosamax use is associated with an increased risk of ONJ, with the risk rising with longer duration of therapy. The condition is rare but serious, and patients should be informed of the signs and symptoms, as well as the importance of dental care and monitoring. The mechanistic link involves bisphosphonate-induced suppression of bone turnover, and the timeline for harm can range from months to years of exposure. For affected patients, causation considerations should include the presence of other risk factors and the temporal relationship between drug initiation and ONJ onset.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that suppresses bone turnover by inhibiting osteoclast activity. This suppression can impair the jawbone's ability to remodel and repair, particularly after dental procedures or infection, leading to osteonecrosis of the jaw (ONJ). Studies show an increased risk with longer duration of use, though absolute risk remains low (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56, https://pubmed.ncbi.nlm.nih.gov/39400702/).

How long does it take for Fosamax to cause jaw problems?

Symptoms such as jaw pain can appear from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Population data show ONJ risk increases after 2-3 years of treatment and is eightfold higher after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the risk factors for developing ONJ while on Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and comorbidities like periodontal disease or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.